Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by longondmxon Aug 05, 2009 3:02pm
446 Views
Post# 16193561

RE: RE: I can't believe how blind so many of you a

RE: RE: I can't believe how blind so many of you athen what is the problem if they just came out and mentioned that in the release...what is the big deal if they spelled it out as it is.  Sure would put alot of this guessing game to rest.  Because frankly, that is all it is, a guessing game at this point when it really doesn;t have to be.

And if they were going to go for more, why would they not just have gone for the approval for the knee first - which we should have gotten yesterday...then tackle the other opportunities with the additional info on a follow-up submission - even if that happened the day after the FDA decision on the knee (ie. today).  Imagine the effect on the stock price if we did it that way?

And don;t tell me that they wanted it all at once...

To me it would make more sense to get the approval on the knee based on meeting the condition of the approvable letter from 2006 and then go for the rest on a follow-up submission.  Instead we are basically starting from scratch - and the FDA can now go back on their previous approvable letter and say it is no longer valid.  I hope I am wrong but what if they do?





Bullboard Posts